Is GoodRx Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for GoodRx Holdings, Inc. has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 38, a Price to Book Value of 2.23, and an EV to EBITDA of 9.64, which are relatively high compared to peers like PropertyGuru Group Ltd. with a P/E of -132.05 and ZipRecruiter, Inc. with a P/E of -12.45, both indicating significant challenges in their valuations.
GoodRx has experienced substantial declines in stock performance, with a 1-year return of -44.33% compared to the S&P 500's 14.08%, and a staggering 5-year return of -92.78% against the S&P 500's 91.29%. This stark contrast reinforces the notion that GoodRx is currently overvalued in its market position.